Longeveron up 7% as frailty drug trial shows promise

Longeveron shares rose 7% after its investigational therapy, laromestrocel, showed positive results in a trial for age-related clinical frailty. The study found that intravenous administration improved physical condition after nine months compared to a placebo. The therapy utilises allogeneic stem cells and was tested on 148 ambulatory individuals.